Tevogen Inc.
Close on Oct 19, 2026
- Market cap
- $25.92M
- P/E (TTM)
- –
- Dividend yield
- –
About Tevogen
Biological Products, (No Diagnostic Substances), SIC 2836
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and neurological disorders. Utilizing its proprietary ExacTcell technology, the company harnesses naturally occurring CD8+ cytotoxic T lymphocytes (killer T cells) to target multiple specific antigens without genetic engineering. Its leading clinical product candidate, TVGN 489, is being developed for the treatment and prevention of COVID-19 and Long COVID, particularly in high-risk elderly and immunocompromised patients. The company’s pipeline also includes investigational therapies targeting viral infections and oncology indications.
The company operates in the biotechnology and healthcare sector, seeking to serve large or underserved patient populations affected by life-threatening illnesses. Its clinical operations and principal executive offices are located in Warren, New Jersey.
Summary of the business section of Tevogen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tevogen Inc.
- Headquarters
- Warren, NJ
- Address
- 15 Independence Boulevard, Suite #210 07059
- Phone
- (646) 807-8832
- Website
- tevogen.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- TVGN
- Other tickers
- TVGNW
- Exchange
- Nasdaq
- IPO date
- Nov 5, 2021
- Shares outstanding
- 7M, Aug 10, 2026
- Public float
- $63.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-50 reverse, Mar 31, 2026; 1-for-50 reverse, Mar 6, 2026
- SEC CIK
- 1860871
- CUSIP
- 88165K200
- ISIN
- US88165K2006
- LEI
- 549300AC21G4NBK9D322
- EIN
- 98-1597194
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ryan H. Saadi | Chief Executive Officer, Director | 11,709,567 |
| Kirti Desai | Chief Financial Officer | 992,983 |
| Neal Flomenberg | See Remarks | 76,940 |
| Sadiq Khan | Chief Commercial Officer | 1,169,618 |
| Jeffrey L. Feike | Director | 131,435 |
| Curtis L. Patton | Director | 139,192 |
| Susan M. Podlogar | Director | 123,678 |
| Keow Lin Goh | Director | 123,678 |
| Victor J. Sordillo | Director | 126,539 |
Corporate history
Events identified from SEC filings